Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

UPDATED: Friday, Jan. 3 at 2:45 p.m. ET GSK’s IL-5 inhibitor Nucala scored a nod in China to treat people with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP), a ...

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma ... 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector device in India.

GSK Stock Performance NYSE GSK opened at $34.08 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. GSK plc has a 1-year low of $31.72 and ...

PLYMOUTH, Mass., January 13, 2025--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based ...

Teva Pharmaceutical Industries Ltd. ADR 0.46% $24.53B ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Funding Freeze Sets Off New Fight Over Trump’s Vision for His Government President Trump’s order freezing trillions of dollars in federal grants and loans seeks to eliminate all spending on ...